Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Recruiting
Observational Study
Lung Cancer
Sarcopenia
Toxicity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 132 (estimated)
- Sponsor
- Instituto Nacional de Cancerologia de Mexico · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
* Candidates for treatment with carboplatin plus paclitaxel 1st line
* Performance status (ECOG 0-2)
* Laboratory studies that demonstrate adequate renal, hepatic an…
Contacts